Cell-Specific Aptamers as Emerging Therapeutics

Table 1

Cell-lines used for cell-SELEX and for corresponding counter selection. The column “When?” indicates whether counter selection was performed before (B) or after (A) the selection, or not at all (—).

Selection cell line	Abbreviation	Counter selection	Abbreviation	When?	Lit.
T-cell line, human ALL	CCRF-CEM	B-cell line, human Burkitt’s lymphoma	Ramos	A	[54]
Carcinoma; small-cell lung cancer	NCI-H69	Carcinoma; large-cell lung cancer	NCI-H661	A	[55]
Mouse liver hepatoma cell line	BNL 1ME A.7R.1 (MEAR)	Normal mouse liver cell line	BNL CL.2	A	[56]
Acute myeloid leukemia	HL60	Acute promyelocytic leukemia	NB4	A	[57]
Human lung carcinoma cells infected with vaccinia virus	A549	Human lung carcinoma cells without infection	A549	A	[58]
Pheochromocytoma of the rat adrenal medulla expressing human RET^C634Y mutant	Pc12/MEN2A	Pheochromocytoma of the rat adrenal medulla parental cells followed by cells expressing human RET^M918T mutant	Pc12 and Pc12/MEN2B	B	[50]
B-cell line, human Burkitt lymphoma	Burkitt lymphoma	None, but FACS to sort out dead cells		—	[10]
Human glioblastoma U251	U251	None		—	[46]
Endothelial cell line YPEN-1	YPEN-1	N9 microglial cells		B	[45]